Loading
NASDAQHealthcareBiotechnology
Latest quote
$1.63
−$0.01 · -0.61%
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.
Previous close
$1.63
−$0.01 · -0.61%
Regular session · ET · Market data may be delayed.
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.
Day range
Current $1.63
52-week range
Current $1.63
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
21
Expensive
Sentiment
50
Mixed
Risk
55
Elevated Risk
Momentum
45
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.
Day range
Current $1.63
52-week range
Current $1.63
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 170K USD | 1M USD | — | — | — |
| Cost of goods sold | 146K USD | — | — | — | — |
| Gross profit | 24K USD | 1M USD | — | — | — |
| Research and development | 7.95M USD | 11.33M USD | 12.73M USD | 43.46M USD | 17.58M USD |
| Selling, general, and administrative | 10.43M USD | 12.08M USD | 12.97M USD | 14.14M USD | 11.47M USD |
| Operating expenses | 18.23M USD | 23.41M USD | 25.71M USD | 57.6M USD | 29.05M USD |
| Interest income | 806K USD | 1.88M USD | 2.72M USD | 1.05M USD | 151K USD |
| Depreciation and amortization | 146K USD | 174K USD | 189K USD | 69K USD | 55K USD |
| Operating income | −18.21M USD | −22.41M USD | −25.71M USD | −57.6M USD | −29.05M USD |
| Net income | −16.59M USD | −19.99M USD | −20.84M USD | −54.23M USD | −27.47M USD |
Company facts updated Sep 13, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Cash distributions grouped by calendar year; partial years are marked.
$0.31
2013 complete year+24.0% since 2011
$0.25
2,011
$0.31
2,013
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Oct 28, 2013 | $0.0021Special | — | — |
Dividend | Apr 4, 2011 | $0.0002Special | — | — |
Ex-dividend Oct 28, 2013
$0.0021
Special
Ex-dividend Apr 4, 2011
$0.0002
Special
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI189.46K0.00%2.3T USD0.03%$376.31+0.82%
Vanguard Extended Market ETFVXF79.64K0.00%93.7B USD0.05%$237.76+0.68%
Dimensional - US Sustainability Core 1 ETFDFSU1640.00%2.35B USD0.15%$47.79+0.82%
Dimensional - US Core Equity 1 ETFDCOR13.120.00%3.58B USD0.14%$83.91+0.75%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFDimensional - US Sustainability Core 1 ETFDFSUDimensional - US Core Equity 1 ETFDCORAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
